In 2012, Makoto Bannai and team from Ajinomoto Co., Inc. tested 7 healthy men (average age 40.6) who slept 25% less than usual for three nights. They took 3 grams of glycine or a fake pill before bed, then rated sleepiness and fatigue using scales and questionnaires, and did computer tests for alertness and focus.

In 2025, Rachel V. Gow and team from the University of Roehampton studied 57 UK individuals (47 children, 10 adults) with ADHD and other neurodivergent conditions like autism. They measured blood levels of key nutrients (omega-3s, zinc, magnesium, B-vitamins, vitamin D) and correlated these with ADHD symptom severity using the Conners Parent Rating Scale.

In 2025, Éva Szabó from the University of Pécs reviewed 8 studies on how dietary fats affect health. Using trials and meta-analyses, they explored saturated fats (SFAs), trans fats (TFAs), and omega-3s, focusing on obesity, diabetes, heart disease, and gut health in humans and animals.

In 2025, T. Iwabe and team studied 17 healthy adults using slow-paced breathing (4-second inhale, 6-second exhale) versus normal breathing. They measured anxiety, brain activity, and heart rate variability before and after stressful images, using the STAI-S scale and EEG.

In 2025, Zhenqi Liu and team from the University of Virginia reviewed studies on GLP-1 drugs like Ozempic, focusing on their impact on cardiorespiratory fitness (CRF), a key predictor of heart health and longevity. While these drugs drive significant weight loss, they also reduce fat-free mass (25-40% of total weight lost), including vital muscle, raising concerns about long-term health.

In 2023, Valentina Paz and team from University College London and Uruguay studied 35,080 adults from the UK Biobank. Using brain scans and self-reported nap habits, they explored links between napping frequency and brain volume, adjusting for age, sex, and lifestyle factors.

In 2025, Rachael Frost and team from Frontiers looked at 209 clinical trials testing 64 over-the-counter products like herbs and supplements for depression in adults. They checked if these helped symptoms more than placebos or matched antidepressants, grouping results by strong evidence (over 10 trials), emerging (2-9), or single studies.

In 2025, Yimeng Wang and team from Peking University studied 88,461 UK Biobank adults who wore wrist trackers for a week, followed for 6.8 years. They checked six sleep traits, like consistent bedtimes and steady rhythms, against 172 diseases, adjusting for age, diet, and lifestyle.

In 2025, researchers from the University of Cambridge studied patients with IBS-D and bile acid diarrhea, analyzing blood samples for the gut hormone INSL5 using a new test from Eli Lilly. They compared INSL5 levels in healthy people and those with chronic diarrhea.

In 2025, Daniel S. Rubin and team from the University of Chicago studied 125 older adults (some frail) using a smartphone app to measure walking pace. They tracked steps per minute and physical abilities like balance and strength over 12 weeks.

In a review by Dr. John Douillard from LifeSpa.com, drawing on studies like the Rotterdam Study (2004) involving 4,807 adults over 55, vitamin K2's role was examined. K2 activates proteins to direct calcium to bones and away from arteries, preventing stiffness and brittleness. The study found at least 32 mcg daily cut cardiovascular death by 50% and all-cause mortality by 25%.

In 2025, Yunxiang Sun and team from Johns Hopkins and Brazilian universities analyzed survey data from over 87,000 adults in Brazil. They used self-reports on diabetes, depression, and diet (via food frequency questionnaires) to check how ultra-processed food (UPF) intake affects the depression-diabetes connection, running stats adjusted for age, income, and more.

In 2025, EMJ reported a study testing ways to cut recreational screen time in adults. Using digital behavior interventions like app timers and mindfulness prompts, researchers tracked phone use and well-being over weeks.

In 2025, Kosuke Kato and team from Emory University studied psilocin, the active compound in magic mushrooms, in human cells and 19-month-old mice (equivalent to ~60-year-old humans). They treated cells with psilocin and gave mice monthly psilocybin doses for weeks, measuring cell lifespan, mouse survival, and aging signs like fur condition.

In 2025, Melody Ding and team from the University of Sydney analyzed 57 studies with over 160,000 people across multiple countries. They used data from wearable devices like pedometers to track daily steps, comparing health outcomes like death rates, heart disease, dementia, and depression against a baseline of 2,000 steps.

In 2025, Kuan-Hung Lin and team from Taipei Medical University studied 60 adults with frequent alcohol-related headaches. In a 4-week trial, half got 100 mg daily vitamin B1 (thiamine), while others received a placebo. They measured headache frequency, blood flow via ultrasound, and brain cell health through blood markers, adjusting for alcohol intake and age.

In 2013, Manfred Lamprecht and team from Graz, Austria, studied 34 obese women in a 12-week trial. They split them into four groups: one got a fruit/vegetable juice powder concentrate, another got the powder plus exercise, a third just exercised, and the last got a placebo. They measured inflammation, oxidative stress, and blood flow markers.

In 2025, a study from AnnalsofIM and others tracked 50,000+ adults with diabetes over years, using health records to compare exercise habits. They grouped people as inactive, insufficiently active, weekend warriors (≥150 min/week in 1–2 sessions), or regularly active, measuring heart-related deaths and overall mortality.

In 2025, Baohua Zheng and team from Chinese hospitals analyzed NHANES data from 2005–2010 on 10,721 adults. They calculated creatine intake from meat sources over two days and checked links to gut issues like chronic constipation and diarrhea using stats that adjusted for age, sex, BMI, and health factors.

In 2025, EMJ published a piece by Marc Beuttler analyzing pharmaceutical companies' role in wellness misinformation. It reviewed industry tactics, like funding influencers and pushing unproven supplements via social media, often bypassing strict regulations. Data showed $4.4 trillion in global wellness market spending, with pharma exploiting gaps in oversight.